NCT00483834View on ClinicalTrials.gov

A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Colorectal Cancer
Interventions
DRUG

Bevacizumab

7.5mg/kg, IV, day 1 of each cycle

DRUG

Irinotecan

200mg/m\^2, IV, day 1 each cycle

DRUG

Capecitabine

1000mg/m\^2 or 750mg/m\^2 for patients over 65yrs old PO BID, day 1-14 each cycle

Trial Locations (1)

M5G 2M9

Princess Margaret Hospital, Toronto

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

University Health Network, Toronto

OTHER

NCT00483834 - A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter